Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 8/19/26 | Xspray Pharma (XSPRAY) | Dasynoc for Acute Lymphoblastic Leukemia (ALL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 8/19/26 | Xspray Pharma (XSPRAY) | Dasynoc for Chronic Myelogenous Leukemia (CML) | Subscribers Only | Subscribers Only | Subscribers Only |
| 8/19/26 | Moderna (MRNA) | mRNA-4157 for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
| 8/17/26 | AstraZeneca (AZN) | Orpathys for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 8/17/26 | AstraZeneca (AZN) | Tagrisso for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |